Nirma Khatri Vadlamudi
Biographic Data
| ID | 7752013 |
|---|---|
| NAME | Nirma Khatri Vadlamudi |
| GIVEN NAMES | Nirma Khatri |
| FAMILY NAME | Vadlamudi |
| SIGNATURE | VADLAMUDI N K |
| ORCID | 0000-0001-5513-7926 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective
Incorporating either PCV20 or PCV15/PPSV23 vaccines in routine vaccination programs for adults aged 50-64 years compared to vaccinating only adults with chronic conditions had an incremental budget impact of $6.5 and $9 billion, respectively, over three years. Budgetary impact was sensitive to number of vaccine doses, cost of vaccine per dose, vaccine coverage proportion and pneumococcal treatment cost across the overall population and sub-groups…
The association of Sars-CoV-2 infection and tuberculosis disease with unfavorable treatment outcomes
Background Whether SARS-CoV-2 infection and its management influence tuberculosis (TB) treatment outcomes is uncertain. We synthesized evidence on the association of SARS-CoV-2 coinfection ( Coinfection Review ) and its management ( Clinical Management Review ) on treatment outcomes among people with tuberculosis (TB) disease. Methods We systematically searched the literature from 1 January 2020 to 6 February 2022. Primary outcomes included: unfa…
No prominent works on this page.
The association of Sars-CoV-2 infection and tuberculosis disease with unfavorable treatment outcomes
Background Whether SARS-CoV-2 infection and its management influence tuberculosis (TB) treatment outcomes is uncertain. We synthesized evidence on the association of SARS-CoV-2 coinfection ( Coinfection Review ) and its management ( Clinical Management Review ) on treatment outcomes among people with tuberculosis (TB) disease. Methods We systematically searched the literature from 1 January 2020 to 6 February 2022. Primary outcomes included: unfa…
A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective
Incorporating either PCV20 or PCV15/PPSV23 vaccines in routine vaccination programs for adults aged 50-64 years compared to vaccinating only adults with chronic conditions had an incremental budget impact of $6.5 and $9 billion, respectively, over three years. Budgetary impact was sensitive to number of vaccine doses, cost of vaccine per dose, vaccine coverage proportion and pneumococcal treatment cost across the overall population and sub-groups…
Adolescent and Pediatric Healthcare (1 work) · Biostatistics (1 work) · Environmental health (1 work) · Epidemiology (1 work) · Immunology (1 work) · Internal Medicine (1 work) · Medicine (1 work) · Pediatrics (1 work) · Pneumococcal conjugate vaccine (1 work) · Pneumococcal disease (1 work)